Cover Image
市場調查報告書

缺血再灌流傷害:開發平台分析

Ischemia Reperfusion Injury - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 253658
出版日期 內容資訊 英文 154 Pages
訂單完成後即時交付
價格
Back to Top
缺血再灌流傷害:開發平台分析 Ischemia Reperfusion Injury - Pipeline Review, H2 2017
出版日期: 2017年07月11日 內容資訊: 英文 154 Pages
簡介

再灌流傷害,是指持續缺血或氧不足的狀態後,由於再度開始供給組織血液而發生的組織傷害。由於缺血狀態時,沒供給血液氧和營養,就算血液循環恢復,正常功能的回復引起氧化壓,也帶來發炎和氧化損傷的結果。治療中,包含抗氧化療法,抗白血球療法,抗補體療法等。

本報告提供缺血再灌流傷害的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

缺血再灌流傷害概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

各調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

各調查中的產品:各大學/研究機關

開發治療藥的企業

  • Amyndas Pharmaceuticals LLC
  • Angion Biomedica Corp.
  • Antipodean Pharmaceuticals, Inc.
  • Bayer AG
  • Biomedica Management Corporation
  • Bolder Biotechnology, Inc.
  • Curatis Pharma GmbH
  • Ensemble Therapeutics Corporation
  • Erimos Pharmaceuticals, LLC
  • Gilead Sciences, Inc.
  • Ischemix, Inc.
  • 興和
  • LG Life Science LTD.
  • Magnus Life Science
  • NeuroVive Pharmaceutical AB
  • Nyken B.V.
  • Omeros Corporation
  • Opsona Therapeutics Limited
  • Orexo AB
  • Pharming Group N.V.
  • PledPharma AB
  • Prolong Pharmaceuticals
  • Proteo, Inc.
  • Prothix BV
  • Stealth BioTherapeutics Inc.
  • Zealand Pharma A/S

治療藥的評估

  • 單獨療法的情況
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AER-271
  • AM/AMBP-1
  • ANV-6L15
  • APP-103
  • BAY-606583
  • BB-3
  • BBT-059
  • bucillamine
  • C1 人類酯酶阻礙因子
  • CMX-2043
  • CRX-526
  • Curaglutide
  • danegaptide
  • Des-Asp Angiotensin 1
  • 缺血再灌流傷害 用ADAM17抑制劑
  • EP-80317
  • GS-459679
  • KN-93
  • LH-021
  • mangafodipir trisodium
  • MG-53
  • mirococept
  • MitoQ
  • 缺血再灌流傷害的單株抗體
  • 循環系統疾病、腎臟移植、腫瘤學 的CD47阻礙單株抗體
  • 腎性缺血再灌流傷害 的IL-16阻礙單株抗體
  • MTP-131
  • NBD 肽
  • NecX
  • Neutrolide
  • NP-202
  • NVP-019
  • NYK-1112
  • 腫瘤學、心臟血管的寡核甘酸
  • OMS-721
  • OPN-305
  • PAC-G31P
  • PIN-201601
  • pitavastatin NP
  • PMC-6
  • PRO-02
  • R-190
  • 缺血再灌流傷害、心肌缺血的 FPR2活性組換形式肽
  • 敗血症、發炎性腸道疾病、急性腎臟損傷、急性輻射症候群、缺血性內臟器官損傷的組換形式蛋白質
  • 缺血再灌流傷害、血栓症的 Robo1 工作組換形式蛋白質Slit2
  • 胰炎、循環系統、免疫學的 CXCL阻礙組換形式蛋白質
  • 缺血再灌流傷害、低氧症的組換形式蛋白質
  • 缺血再灌流傷害的 PTCH1 工作組換形式蛋白質
  • 心肌病、缺血再灌流傷害的白細胞介素-1受體較量組換形式蛋白質
  • Sanguinate
  • 再灌流傷害、心臟病發作的小分子
  • 再灌流傷害的δ類鴉片物質促效劑
  • 心肌缺血、缺血再灌流傷害的精胺酸酶1、2阻礙小分子
  • 缺血再灌流傷害的小分子
  • 缺血再灌流傷害、發炎性疾病的小分子
  • 缺血再灌流傷害的 SGK-1活性小分子
  • 缺血再灌流傷害、老年癡呆症的親環蛋白 D 阻礙小分子
  • 循環系統疾病的 PDE5阻礙小分子
  • 缺血再灌流傷害的合成肽
  • 腫瘤學、免疫學、循環系統傷害的合成肽
  • terameprocol
  • tiomolibdate diammonium
  • tiprelestat
  • TMS-007
  • UCF-101
  • UWA-TAT

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9501IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H2 2017, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.

Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 4, 1, 29 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 21 and 4 molecules, respectively.

Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ischemia Reperfusion Injury (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ischemia Reperfusion Injury (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Ischemia Reperfusion Injury - Overview
  • Ischemia Reperfusion Injury - Therapeutics Development
  • Ischemia Reperfusion Injury - Therapeutics Assessment
  • Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development
  • Ischemia Reperfusion Injury - Drug Profiles
  • Ischemia Reperfusion Injury - Dormant Projects
  • Ischemia Reperfusion Injury - Discontinued Products
  • Ischemia Reperfusion Injury - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Ischemia Reperfusion Injury, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by Angion Biomedica Corp, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by Biomedica Management Corp, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology Inc, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by Catalyst Biosciences Inc, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by Conatus Pharmaceuticals Inc, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by Corline Biomedical AB, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by Gilead Sciences Inc, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by Glucox Biotech AB, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by Hope Pharmaceuticals Inc, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by Ischemix Inc, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by Kowa Company Ltd, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by NovelMed Therapeutics Inc, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by Omeros Corp, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by Opsona Therapeutics Ltd, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by Orexo AB, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by Pharming Group NV, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by Prolong Pharmaceuticals LLC, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by Prothix BV, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by Reata Pharmaceuticals Inc, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by Recordati SpA, H2 2017
  • Ischemia Reperfusion Injury - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2017
  • Ischemia Reperfusion Injury - Dormant Projects, H2 2017
  • Ischemia Reperfusion Injury - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Ischemia Reperfusion Injury - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Ischemia Reperfusion Injury - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Ischemia Reperfusion Injury, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top